APTO

0.279

63.92% 0.1088

Handel nachbörslich: .23 -0.049 -17.56%

Aptose Biosciences Inc (APTO)

Überblick Nachrichten Preisverlauf Financials Warum fällt APTO? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.1702

Offen:

$0.27

24-Stunden-Volumen:

304.66M

Relative Volume:

54.79

Marktkapitalisierung:

$16.61M

Einnahmen:

Nettoeinkommen (Verlust:

$-51.21M

KGV:

-0.0357

EPS:

-7.82

Netto-Cashflow:

$-44.62M

1W Leistung:

+44.56%

1M Leistung:

+2.16%

6M Leistung:

-65.11%

1J Leistung:

-88.03%

1-Tages-Spanne:

$0.2106

$0.3895

1-Wochen-Bereich:

$0.17

$0.3895

52-Wochen-Spanne:

$0.13

$2.68

Aptose Biosciences Inc Stock (APTO) Company Profile

Firmenname

Aptose Biosciences Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

310-849-8060

Adresse

66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

APTO's Discussions on Twitter

Vergleichen Sie APTO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
APTO Aptose Biosciences Inc	0.279	16.61M	0	-51.21M	-44.62M	-7.72
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-10-19	Eingeleitet	Cantor Fitzgerald	Overweight
2020-09-22	Eingeleitet	Alliance Global Partners	Buy
2020-02-20	Eingeleitet	Maxim Group	Buy
2020-02-06	Bestätigt	H.C. Wainwright	Buy
2020-01-09	Eingeleitet	Piper Sandler	Overweight
2019-03-01	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-16	Eingeleitet	B. Riley FBR	Buy
2017-12-13	Bestätigt	H.C. Wainwright	Buy
2017-10-23	Fortgesetzt	ROTH Capital	Buy
2017-09-07	Hochstufung	H.C. Wainwright	Neutral → Buy
2017-06-08	Eingeleitet	Rodman & Renshaw	Neutral

Alle ansehen

Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten

Dec 19, 2024

Aptose gets Nasdaq extension to regain compliance - MSN

Dec 19, 2024

Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewswire

Dec 19, 2024

Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan

Dec 19, 2024

Dec 14, 2024

Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register

Dec 14, 2024

Dec 13, 2024

SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow

Dec 13, 2024

Dec 12, 2024

Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire

Dec 12, 2024

Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan

Dec 12, 2024

Dec 11, 2024

Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart

Dec 11, 2024

Dec 09, 2024

Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire

Dec 09, 2024

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - Marketscreener.com

Dec 09, 2024

Aptose's Tuspetinib Shows Breakthrough 60% Response Rate in AML Treatment at ASH Meeting - StockTitan

Dec 09, 2024

Dec 07, 2024

StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World

Dec 07, 2024

Dec 04, 2024

Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada

Dec 04, 2024

Dec 03, 2024

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire

Dec 03, 2024

Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan

Dec 03, 2024

Nov 30, 2024